NCT07476677 2026-03-17
ANDARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
Clinical Trials
47 trialsNCT07103018 2026-03-16
STRIKE-001
K36 Therapeutics, Inc.
Phase 1 Recruiting
NCT06173362 2026-03-13
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
Phase 2 Recruiting
NCT06463457 2026-03-09
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05999968 2026-03-05
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
Phase 1 Completed
NCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT05617885 2026-02-27
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05997615 2026-02-24
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT06627530 2026-02-11
COAction
Brazilian Clinical Research Institute
Phase 4 Active not recruiting
NCT05059236 2026-02-09
ARASEC
Bayer
Phase 2 Active not recruiting
NCT06631521 2026-02-05
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
AdventHealth
Phase 1 Recruiting
NCT05348876 2026-01-30
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Bayer
Phase 4 Recruiting
NCT06120491 2026-01-21
EvoPAR-PR01
AstraZeneca
Phase 3 Recruiting
NCT06734130 2026-01-21
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT05519449 2026-01-20
ENGAGER-PSMA-01
Janux Therapeutics
Phase 1 Recruiting
NCT06592924 2026-01-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06660862 2026-01-08
Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
University of Chicago
Phase 4 Not yet recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT04025372 2025-12-15
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT07282197 2025-12-15
Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
Peking University First Hospital
Phase 2 Not yet recruiting
NCT04335682 2025-11-04
ARACOG
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
NCT02972060 2025-09-19
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT07172685 2025-09-15
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
Qilu Hospital of Shandong University
Phase NA Recruiting
NCT03385655 2025-08-21
Prostate Cancer Biomarker Enrichment and Treatment Selection
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04319783 2025-08-21
DECREASE
Trans Tasman Radiation Oncology Group
Phase 2 Active not recruiting
NCT05413421 2025-08-11
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
ORIC Pharmaceuticals
Phase 1 Recruiting
NCT05171387 2025-06-22
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Bayer
Phase 2 Completed
NCT07027124 2025-06-18
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Not yet recruiting
NCT04925648 2025-05-15
PICASSO
St Vincent's Hospital, Sydney
Phase 2 Recruiting
NCT06190899 2025-03-21
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity Inc
Phase 1/2 Recruiting
NCT04070209 2024-12-04
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Recruiting
NCT06575257 2024-08-28
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
Xijing Hospital
Phase 2 Recruiting
NCT02933801 2024-03-13
ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.
Swiss Cancer Institute
Phase 2 Terminated
NCT05116475 2024-03-12
ALADDIN
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04641078 2024-02-28
DART
University Hospital, Ghent
Phase 2 Unknown
NCT06282588 2024-02-28
THUNDER
Cancer Research Antwerp
Phase 2/3 Recruiting
NCT04176081 2024-01-24
SChLAP/IDC
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT04737109 2023-11-13
ADDItion
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT05771896 2023-09-14
CARE
GenesisCare USA
Phase 3 Withdrawn
NCT05900973 2023-08-07
A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
D'Or Institute for Research and Education
Phase 2 Unknown
NCT04136353 2023-07-28
DASL-HiCaP
University of Sydney
Phase 3 Active not recruiting
NCT05249712 2023-01-03
Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT01784757 2021-03-17
ARAFOR
Orion Corporation, Orion Pharma
Phase 1 Completed
NCT03237416 2018-11-06
Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers
Bayer
Phase 1 Completed
NCT01317641 2017-03-29
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Orion Corporation, Orion Pharma
Phase 1/2 Completed
NCT01429064 2017-02-20
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Orion Corporation, Orion Pharma
Phase 2 Completed